0001209191-18-010218.txt : 20180214
0001209191-18-010218.hdr.sgml : 20180214
20180214212503
ACCESSION NUMBER: 0001209191-18-010218
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20180213
FILED AS OF DATE: 20180214
DATE AS OF CHANGE: 20180214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Finney Michael J.
CENTRAL INDEX KEY: 0001650978
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35285
FILM NUMBER: 18615934
MAIL ADDRESS:
STREET 1: 385 OYSTER POINT BLVD., SUITE 9A
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aviragen Therapeutics, Inc.
CENTRAL INDEX KEY: 0000072444
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 591212264
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 2500 NORTHWINDS PARKWAY, SUITE 100
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30009
BUSINESS PHONE: 301-770-3099
MAIL ADDRESS:
STREET 1: 2500 NORTHWINDS PARKWAY, SUITE 100
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30009
FORMER COMPANY:
FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20121113
FORMER COMPANY:
FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS
DATE OF NAME CHANGE: 20100719
FORMER COMPANY:
FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS
DATE OF NAME CHANGE: 20020304
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2018-02-13
1
0000072444
Aviragen Therapeutics, Inc.
VXRT
0001650978
Finney Michael J.
395 OYSTER POINT BLVD, SUITE 405
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
/s/ Michael J. Finney, Ph.D.
2018-02-13
EX-24.3_769125
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Wouter W. Latour, M.D., John M. Harland, and Josh Seidenfeld, signing
individually, the undersigned's true and lawful attorneys-in fact and agents to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director or beneficial owner of more than 10% of a registered
class of securities of Vaxart, Inc. (f/k/a Aviragen Therapeutics, Inc.) (the
"Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance
with Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to execute such Forms 3, 4 or 5 (including any
amendments thereto) and timely file such forms with the United States Securities
and Exchange Commission and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact is no longer employed by the Company
or Cooley LLP.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of February 9, 2018.
/s/ Michael J. Finney
Michael J. Finney, Ph.D.